Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019163 (hepatitis B)
 38,309 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Several items characterize the papular acrodermatitis: 1. the clinical picture and the localisation 2. inguinal and axillary lymphadenitis 3. acute usually anicteric hepatitis 4. presence of hepatitis B antigen in all patients. Other members of the family are carriers of HB-Ag, too. One of them usually had icteric hepatitis weeks before or after PAC. At present we consider PAC as the clinical disease due to the primary infection of HB-Ag in childhood. The cycle of HB Ag is shown in a scheme. It suggests why the disease is rare, asymptomatic infections occurring in the majority of the cases. It appears in children without HB-antibodies and a particular reactive condition. After parenteral inoculation PAC and lymphadenitis do not develop. Some chronic HB Ag carriers may have become so after PAC in the childhood.
 ...
PMID:Akrodermatitis papulosa infantilis. An Australia antigen disease. 83 58

Sera collected from 1,118 healthy children and adults aged between four years and 90 years during the period 1989 to 1990, were tested for serological markers of hepatitis A virus (HAV) [antibody to HAV (anti-HAV)] and hepatitis B virus (HBV) [hepatitis B surface antigen (HBsAg) and antibody to hepatitis B surface antigen (anti-HBsAb)]. The overall prevalence rates of anti-HAV, HBsAg, and anti-HBV were 20.2%, 0.36%, and 5.1%, respectively. No body was found to be positive for anti-HAV below 30 years of age but more than 70% of the adults aged 50 years or over were positive for anti-HAV. The level of exposure of HAV infection is declining in Japan and paradoxically at the same time a vast majority of people are becoming susceptible to more severe illness. The fall in prevalence of HBsAg possibly represents the positive impact of ongoing vaccination programs and other preventive measures against HBV.
Asia Pac J Public Health
PMID:The seroepidemiology of hepatitis A and B in a Japanese town. 133 21

This study was based on a hepatitis B screening program conducted in one of the states in Malaysia in 1989. The majority (84.6%) of the 2986 health employees were screened. One quarter (25%) was found to have serological markers for the Hepatitis B Virus (HBV); 2.1% had Hepatitis B surface Antigen (HBsAg) and 22.8% had antibody to the Hepatitis B surface Antigen (anti-HBs). The occurrence of HBsAg was higher in ethnic Chinese (6.3%) compared to Malays (1.8%) and Indians (0.9%), even when analyzed by sex, but not with age, type of institution and geographical locality. The distribution of anti-HBs was higher with ethnic Chinese (41.6%), male sex (27.2%) and age. There was a wide variation of the prevalence of serological markers among occupations and increased relative risks of HBsAg were found among medical assistants (RR3.7; 95% CI 1.4-9.1) and laboratory staff (RR 3.2; 95% CI 1-8.8), and that of anti-HBs among medical assistants (RR 2.8; 95% CI 1.8-3.7). The variations of HBsAg among occupations by type of institutions was marginal while that of anti-HBs was higher among attendants and midwives in hospitals, medical assistants in health departments, and assistant nurses and dentists in dental centers. The patterns of distribution of serological markers of HBV among health staff reflect the situation in the community with high endemicity and resemble specific occupational factors noted in previous studies in the West.
Asia Pac J Public Health
PMID:Prevalence of hepatitis B surface antigen and antibody among health care employees in Negri Sembilan, Malaysia, 1989. 134

A comparative study was conducted to evaluate the immunogenicity of hepatitis B vaccine in low and normal birth weight infants. Hepatitis B vaccine (Hevac B Pasteur) was given to 50 low birth weight infants and 50 controls, matched by sex and date of delivery. The vaccine was given at birth, 1, 2 and 12 months of age. HBsAg and anti-HBs were assessed at birth, 4, 9 and 13 months of age by the micro-ELISA technique. Using the geometric mean titre of anti-HBs and the seroconversion rate as indicators, the immunogenicity of hepatitis B vaccine in low birth weight infants was as good as in normal birth weight infants.
Asian Pac J Allergy Immunol 1992 Jun
PMID:Comparison of immunogenicity of hepatitis B vaccine between low and normal birth weight infants. 141 86

A solid waste scavenger community at On-Nooch dump site in Bangkok was investigated. The purpose was to identify the dimensions of the public health risk to this group of people and their community due to exposure to hazardous conditions from waste materials. A cross-sectional descriptive study utilizing field surveys and measurements was performed. The demographic, socioeconomic, health related and environmental characteristics of this community were examined. Health complaints and injuries were inventoried among scavengers. Prevalence of childhood respiratory illness was high especially in those households where smoking was present. Intestinal helminthic and protozoan infection in children were detected. Six individuals with possible HIV infection and a number of Hepatitis B anti-genemia were found among male respondents. An appreciable proportion of respondents fell below normal when tested for lung function. Air pollution measurements showed acceptable ambient air levels except for particulate matters. Water quality was low for both potable and nonpotable water.
Asia Pac J Public Health 1991
PMID:Solid waste scavenger community: an investigation in Bangkok, Thailand. 179 34

The dehydration-rehydration vesicle (DRV) method was used to encapsulate hepatitis B surface antigen (HBsAg) in phosphatidylcholine (PC) and distearoyl phosphatidylcholine (DSPC) liposomes giving entrapment values of 31.7% and 33.1% respectively. A comparison of antibody levels, as determined by ELISA, in the primary and secondary immune responses in mice immunized twice with 1 microgram HBsAg free, or in formulations of PC DRV, DSPC DRV, Syntex Adjuvant Formulation (SAF), alum and Freund's Complete Adjuvant (FCA) showed that by far, FCA was the best adjuvant in both the primary and secondary IgG1, IgG2a and IgG2b responses. In the secondary response, apart from FCA, DSPC DRV and SAF were equally efficacious and better adjuvants than alum and PC DRV for the IgG2a and IgG2b subclasses. SAF was a better adjuvant for HBsAg than alum, DSPC DRV and PC DRV (in descending order of efficacy) in the secondary IgG1 response.
Asian Pac J Allergy Immunol 1991 Dec
PMID:A study of the efficacy of liposomes in comparison to new and established adjuvants in potentiating the antibody response against hepatitis B virus surface antigen. 180 65

A low dose of recombinant DNA hepatitis B vaccine (HB-VAX II, MSD) was tested for efficacy in the prevention of perinatal hepatitis B virus (HBV) transmission in normal and high-risk neonates born from HBsAg carrier mothers. A dose of 2.5 micrograms recombinant vaccine was injected intramuscularly at 0, 1, 2 and 12 months of age to 30 newborns from HBsAg negative mother (group I), 30 from HBeAg negative/HBsAg carrier mother (group II) and 30 from HBeAg positive/HBsAg carrier mother (group III). The incidence of persistent HBsAg carrier infants at 13 months of age was 0, 0, and 30.4 percent in groups I, II and III, respectively. The protective efficacy in high risk infants in group III was 65.7 percent. The seroconversion at month 4, after the third dose of vaccination was 96.3, 95.7 and 100 percent in group I, group II and group III, respectively. After a booster dose of vaccination at 12 months of age, the seroconversion rose to 100 percent at month 13 in all three groups. The geometric mean titer (GMT) of anti-HBs antibody at 13 months of age were 2,092, 1,657 and 1,938 mIU/ml in group I, group II and group III, respectively. It is concluded that the low dose (2.5 micrograms) recombinant hepatitis B vaccine using alone is effective in prevention of perinatal HBV transmission in low risk infants (groups I and II), but it is less effective in high risk infants (group III).(ABSTRACT TRUNCATED AT 250 WORDS)
Asian Pac J Allergy Immunol 1991 Dec
PMID:Immunogenicity and protective efficacy of low dose recombinant DNA hepatitis B vaccine in normal and high-risk neonates. 183 54

Nearly 1,000 serum samples were obtained from apparently healthy workers of both sexes in various factories in Beijing during 1988-1989 and were examined for hepatitis B virus infection markers by radioimmunoassay. The overall prevalence (all ages and both sexes combined) of cases positive for HBsAg, anti-HBs and anti-HBc were 3.7%, 36.6% and 37.7%, respectively and the rate of those negative to any of the three markers studied was 56.1%. The infection rate was lower than the values reported early in the 1980s for Beijing populations or the values for populations in other parts of China.
Asia Pac J Public Health 1991
PMID:Prevalence of hepatitis B virus infection markers among factory workers in Beijing, China. 184 25

A total of 70 serum samples taken from patients with hepatocellular carcinoma (HCC), acute viral hepatitis and cirrhosis and normal individuals were tested in a binding inhibition immunofluorescence assay using 5 mouse monoclonal antibodies (2G9, 3H11, 3H12, 1C7, 3H5) specific for hepatoma cells. Seven out of the 30 HCC sera (23.3%) inhibited the binding of one of these antibodies, 3H11. This detection of antigen 3H11 or antigens of similar structure in HCC sera was significantly more frequent than in control sera (1/40 = 2.5%) (Fisher's exact test, p = 0.009; df = 1, relative risk calculated by the odds ratio in a 2 x 2 table = 12.0). The presence of this antigen was unrelated to the hepatitis B surface antigen and alphafetoprotein status. Thus it would be of value particularly for the detection of hepatitis B negative or alphafetoprotein negative liver cancers.
Asian Pac J Allergy Immunol 1990 Dec
PMID:Detection of tumour antigens in sera of patients with hepatocellular carcinoma using monoclonal antibodies. 196 8

Four fibrolamellar liver carcinomas were surgically removed and were postoperatively examined. Three patients are alive roughly three years from surgery, and there are no signs of imminent recurrence, while the fourth case was diagnosed only two months back. The carcinomas had developed in non-cirrhotic livers which also produced negative responses to serological tests for hepatitis B. In flow cytometry, DNA indices were indicative of diploidy in two cases and aneuploidy in the other two. The highest DNA index value was recorded from the smallest tumour which could be assigned to the category of "minute HCC". No correlation was found to exist either between age, sex, and DNA index. Positive CEA reaction was immunohistochemically recorded from few tumour cells, whereas negative AFP responses were exhibited by all four tumours. Appearance of AAT in tumour cells was detected in three cases. High degree of differentiation, similarity between tumour and liver cells, and oncocytoid nature of cells were revealed by optical light and electron microscopy. This high degree of differentiation was additionally confirmed by two factors: glucose-6-phosphatase activity was preserved in all four tumours, adenosinetriphosphatase activity was histochemically detectable from certain points of the tumour cell membrane. Gamma-glutamyl-transpeptidase activity, too, was very strongly pronounced in all tumour cells, which, however, cannot be interpreted as a sign of differentiation. Membrane-bordered "dense-core" granules were visible in few tumour cells in two cases. Intensive granular serotonin reactions were immunohistochemically recorded from the majority of tumour cells in the same cases. Our histochemical and ultrastructural parameters have produced clear-cut evidence to the hepatocyte nature of FLC cells. Yet, the presence of secretory granules and positive serotonin reaction might possibly support the assumption that the FLC originates from those pluripotent cells of the liver which may develop in two directions, depending on the individual case, to become either hepatocytes or neurosecretory cells.
 ...
PMID:[Fibrolamellar liver carcinoma]. 215 93


1 2 3 4 5 6 7 8 9 10 Next >>